NovoCure NVCR Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $93.55M-42.9% | $163.77M-32.0% | $240.82M+109% | $115.33M-44.8% | ||
| $354.13M-55.5% | $796.11M+18.9% | $669.8M-21.6% | $854.1M+17.2% | ||
| $41.11M+17.2% | $35.09M-8.0% | $38.15M+29.9% | $29.38M+20.3% | ||
| $646.73M-41.6% | $1.11B+7.0% | $1.03B-6.9% | $1.11B+3.5% | ||
| $77.61M-0.1% | $77.66M+50.9% | $51.48M+57.5% | $32.68M+44.0% | ||
| $157.6M+17.4% | $134.21M+20.1% | $111.72M+39.4% | $80.12M+21.4% | ||
| $804.33M-35.2% | $1.24B+8.3% | $1.15B-3.8% | $1.19B+4.6% | ||
| $122.23M+16.3% | $105.09M+11.3% | $94.39M+10.8% | $85.2M+17.4% | ||
| $223.23M-70.5% | $756.39M+322% | $179.12M+12.8% | $158.78M+11.3% | ||
| $240.63M+93.7% | $124.21M-79.5% | $604.52M+2.2% | $591.7M+0.9% | ||
| $463.86M-47.3% | $880.61M+12.4% | $783.63M+4.4% | $750.48M+2.9% | ||
| $0— | $0— | $0— | $0— | ||
| -$1.29B-11.8% | -$1.15B-17.1% | -$985.5M-26.6% | -$778.46M-13.5% | ||
| $340.47M-5.5% | $360.18M-0.6% | $362.5M-17.8% | $441.17M+7.5% | ||
| $804.33M-35.2% | $1.24B+8.3% | $1.15B-3.8% | $1.19B+4.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can NovoCure cover its short-term obligations?
- Its current ratio is 2.90 — current assets exceed current liabilities.
- Where does NovoCure's balance sheet data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.